In the past two decades, activated UPR has been reported in ischemia/reperfusion [43–46], dilated cardiomyopathy [21], myocardial infarction [23,47–49], hypertension [50–53], diabetic cardiomyopathy [25,54,55], and heart failure [6,33,51,56–58] with increased expression of ER chaperones (Grp78 and calreticulin) and effectors from all three UPR arms. Here, HSPA5 is linked to heart failure.